These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127 [TBL] [Abstract][Full Text] [Related]
7. Hematopoietic growth factors: ESMO recommendations for the applications. Greil R; Psenak O; Roila F; Ann Oncol; 2008 May; 19 Suppl 2():ii116-8. PubMed ID: 18456747 [No Abstract] [Full Text] [Related]
8. Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy. Anderlini P; Champlin R Drugs; 2002; 62 Suppl 1():79-88. PubMed ID: 12479596 [TBL] [Abstract][Full Text] [Related]
9. Colony-stimulating factors for febrile neutropenia during cancer therapy. Bennett CL; Djulbegovic B; Norris LB; Armitage JO N Engl J Med; 2013 Mar; 368(12):1131-9. PubMed ID: 23514290 [TBL] [Abstract][Full Text] [Related]
10. Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. Strassels SA; Dickson M; Norris LB; Bennett CL J Natl Cancer Inst; 2013 Aug; 105(15):1072-3. PubMed ID: 23873406 [No Abstract] [Full Text] [Related]
11. New treatment options for managing chemotherapy-induced neutropenia. Valley AW Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S11-7. PubMed ID: 12166032 [TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Crawford J Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597 [TBL] [Abstract][Full Text] [Related]
13. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Crawford J; Caserta C; Roila F; Ann Oncol; 2010 May; 21 Suppl 5():v248-51. PubMed ID: 20555091 [No Abstract] [Full Text] [Related]
14. Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia. Petros WP Pharmacotherapy; 2003 Aug; 23(8 Pt 2):1S-2S; quiz 20S-23S. PubMed ID: 12921215 [No Abstract] [Full Text] [Related]
15. An analysis of current neutropenia therapies, including pegfilgrastim. Gabrilove JL Clin Cornerstone; 2006; 8 Suppl 5():S19-28. PubMed ID: 17379160 [TBL] [Abstract][Full Text] [Related]
17. Hematopoietic growth factors for chemotherapy-induced neutropenia. Yalçin S Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202 [No Abstract] [Full Text] [Related]
18. Feasibility and kinetics of CD34 Takhar H; Mislang AR; Singhal N; Brown MP Asia Pac J Clin Oncol; 2017 Feb; 13(1):79-86. PubMed ID: 27649817 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Lyman G; Lalla A; Barron R; Dubois RW Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients. Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]